Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.

Liberante FG, Pellagatti A, Boncheva V, Bowen DT, Mills KI, Boultwood J, Guinn BA.

Br J Haematol. 2013 Jul;162(2):282-5. doi: 10.1111/bjh.12352. Epub 2013 Apr 18. No abstract available.

PMID:
23594062
2.

PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.

Qin YZ, Zhu HH, Liu YR, Wang YZ, Shi HX, Lai YY, Xu LP, Liu DH, Jiang Q, Li LD, Jiang B, Liu KY, Huang XJ.

Leuk Lymphoma. 2013 Jul;54(7):1442-9. doi: 10.3109/10428194.2012.743656. Epub 2012 Nov 26.

PMID:
23110703
3.

PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.

Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R.

Am J Hematol. 2005 Aug;79(4):257-61.

4.

Prevalence and prognostic and predictive relevance of PRAME in breast cancer.

Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L.

Breast Cancer Res Treat. 2008 May;109(2):359-65. Epub 2007 Jul 12.

PMID:
17624586
5.

Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.

Tajeddine N, Louis M, Vermylen C, Gala JL, Tombal B, Gailly P.

Leuk Lymphoma. 2008 Jun;49(6):1123-31. doi: 10.1080/10428190802035933.

PMID:
18452107
6.

PRAME expression and clinical outcome of breast cancer.

Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R.

Br J Cancer. 2008 Aug 5;99(3):398-403. doi: 10.1038/sj.bjc.6604494. Epub 2008 Jul 22.

7.

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

Epping MT, Bernards R.

Cancer Res. 2006 Nov 15;66(22):10639-42. Review.

8.

Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome.

Vasikova A, Budinska E, Belickova M, Cermak J, Bruchova H.

Neoplasma. 2009;56(4):335-42.

PMID:
19469654
9.

PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.

Brenne K, Nymoen DA, Reich R, Davidson B.

Am J Clin Pathol. 2012 Feb;137(2):240-7. doi: 10.1309/AJCPGA95KVSAUDMF.

10.

Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome.

Qian J, Zhu ZH, Lin J, Ming Yao DM, Li Y, Yang J, Wang CZ.

Br J Haematol. 2011 Jul;154(1):153-5. doi: 10.1111/j.1365-2141.2011.08585.x. Epub 2011 Apr 22. No abstract available.

PMID:
21517806
11.

Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.

Spanaki A, Perdikogianni C, Linardakis E, Kalmanti M.

Leuk Res. 2007 May;31(5):639-42. Epub 2006 Jul 24.

PMID:
16860864
12.

PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.

Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G.

Leuk Res. 2007 Mar;31(3):365-9. Epub 2006 Aug 17.

PMID:
16914202
13.

Expression and prognostic relevance of PRAME in primary osteosarcoma.

Tan P, Zou C, Yong B, Han J, Zhang L, Su Q, Yin J, Wang J, Huang G, Peng T, Shen J.

Biochem Biophys Res Commun. 2012 Mar 23;419(4):801-8. doi: 10.1016/j.bbrc.2012.02.110. Epub 2012 Feb 27.

PMID:
22390931
14.

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.

Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M.

Ann Hematol. 2012 Dec;91(12):1887-95. doi: 10.1007/s00277-012-1538-7. Epub 2012 Aug 9.

PMID:
22875062
15.

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.

Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M.

Haematologica. 2008 Dec;93(12):1797-805. doi: 10.3324/haematol.13214. Epub 2008 Sep 24.

16.

Is everything known in all faces of iceberg in PRAME?

Paydas S.

Leuk Res. 2008 Sep;32(9):1356-7. doi: 10.1016/j.leukres.2008.02.024. Epub 2008 Apr 9. No abstract available.

PMID:
18400297
17.

Differentially expressed genes in adult familial myelodysplastic syndromes.

Pradhan A, Mijovic A, Mills K, Cumber P, Westwood N, Mufti GJ, Rassool FV.

Leukemia. 2004 Mar;18(3):449-59.

PMID:
14737073
18.

PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.

van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG.

Br J Haematol. 1998 Sep;102(5):1376-9.

PMID:
9753074
19.
20.

Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.

Zhang W, Chi K, Zhang Y, Ma B, Shi J, Chen Y, Lei P, Li Y, Sun K.

Acta Haematol. 2013;130(4):297-304. doi: 10.1159/000351166. Epub 2013 Aug 31.

PMID:
24008770
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk